Alzheimer's & Cognition
News
FDA approves second antiamyloid for Alzheimer’s disease
Like its controversial cousin aducanumab, lecanemab was approved under the FDA’s accelerated approval pathway.
News
FDA considers regulating CBD products
The products can have drug-like effects on the body and contain CBD (cannabidiol) and THC (tetrahydrocannabinol).
From the Journals
Strong link between muscle strength, mobility, and brain health
“The implication is that muscular strength and mobility influence brain health.”
News from the FDA/CDC
Alzheimer’s Association to CMS: Ditch restraints on amyloid drugs
The CMS coverage restrictions for anti-amyloid drugs were finalized in April on the...
Conference Coverage
Antipsychotic shows benefit for Alzheimer’s agitation
Currently, there’s no Food and Drug Administration–approved treatment for agitation in AD.
Commentary
Mindfulness, exercise strike out in memory trial
Meditation and exercise do not appear to be the fountain of youth.
From the Journals
Noninvasive laser therapy tied to improved short-term memory
Patients with attention-related conditions ‘could benefit from this type of treatment,’ expert says.
Conference Coverage
SSRI tied to improved cognition in comorbid depression, dementia
Evidence suggests the drug’s receptor targets “have the potential to modulate neurotransmitter systems that are essential for regulation of...
Feature
How your voice could reveal hidden disease
For some of us, when a disease begins or when our mental health declines, our voice changes.
Feature
Mind the geriatrician gap
In 2022, only 43% of the nation’s 177 geriatrics fellowship slots were filled.
From the Journals
Ultraprocessed foods tied to faster rate of cognitive decline
Study results align with previous research that found a link between a diet high in UPFs and increased dementia risk.